Global Hydralazine Injections Market Size, Share, and Trends Analysis Report, By Application (High Blood Pressure and Congestive Heart Failure) and By Distribution Channel (Hospital Pharmacies and Retail Drug Stores), Forecast (2022-2028)

The global hydralazine injections market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Hydralazine injections are the vasodilator class of medication used for the treatment of high blood pressure and congestive heart failure. The major factor attributing to the growth of the global hydralazine injections market is the increasing application of hydralazine injections in congestive heart failure due to its rising prevalence. According to the Heart Failure Society of America (HFSA), around 5.5 million new cases of congestive heart failure are diagnosed every year in the US alone with around 5 million people living with congestive heart failure in the US. Congestive heart failure can affect people of all ages, including children, adults, and elders. Around 1.4 million people with congestive heart failure are under the age of 60 years and after 60 years of age, the prevalence of congestive heart failure is around 10 in every 1,000 people in the US.

 

Additionally, the application of hydralazine injections in the treatment of high blood pressure is also increasing across the globe. According to the Centers for Disease Control and Prevention (CDC), around 116 million people in the US have high blood pressure representing around 47% of the total adult population of the country. Having high blood pressure can increase the risk of heart disease and heart strokes which can be the major cause of mortality. More than 5 million mortality were caused due to hypertension in the US in 2019. Only one in every 4 adults with high blood pressure has their condition under control More than half of the adults with high blood pressure have uncontrolled conditions. Thus, boosting the demand for hydralazine injections.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Novartis International AG, American Regents Inc., Fresenius, SteriMax Inc., and Akorn Operating Co. LLC, among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Hydralazine Injections  Market Report by Segment

By Application

• Multiple Myeloma
• Mantle Cell Lymphoma

By Distribution Channel

• Hospital Pharmacies
• Retail Drug Stores

 

Global Hydralazine Injections  Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa